Dr. Guitera on the RADICAL Trial for Melanoma

Video

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, University of Sydney, discusses the RADICAL trial of patients with melanoma.

The phase III multicenter RADICAL trial is investigating patients with lentigo maligna melanoma. Lengito maligna is an early stage of melanoma that is generally found in elderly patients and is difficult to operate on.

In the trial, patients were randomized to radiotherapy or imiquimod to determine the efficacy of these treatments. The primary endpoint is treatment failure at 6 months that is biopsy proven. Secondary endpoints include treatment failure at 12 months and 24 months.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD